Latest market price
24.54
-0.70-2.77%
STAAQT35STAAR Surgical Company·NASDAQ
24.54-2.77%
TA
Loading chart...
Screen all →
Snapshot
Index—P/E—EPS (ttm)0.08Insider Own34.87%Shs Outstand50.14MPerf Week8.54%
Market Cap1.23BForward P/E44.87EPS next Y0.55Insider Trans0.00%Shs Float49.74MPerf Month9.65%
Enterprise Value1.08BPEG7.99EPS next Q0.05Short Float7.43%Perf Quarter0.82%
Income4.00MP/S3.61EPS this Y—Short Ratio3.75Perf Half Y-9.75%
Sales341.00MP/B3.37EPS next Y88.23%ROA0.81%Short Interest3.70MPerf YTD6.28%
Book/sh7.28P/C6.80EPS next 5Y38.37%ROE1.08%52W High35.87 -31.59%Perf Year-7.71%
Cash/sh3.61P/FCF—EPS past 3/5Y—ROIC1.90%52W Low15.59 57.41%Perf 3Y-36.70%
Dividend Est.—EV/EBITDA33.74Sales past 3/5Y-5.59% 7.95%Gross Margin76.23%Volatility4.85% 3.82%Perf 5Y-79.96%
Dividend TTM—EV/Sales3.17EPS Y/Y TTM—Oper. Margin10.32%ATR (14)0.96Perf 10Y159.68%
Dividend Ex-Date—Quick Ratio4.03Sales Y/Y TTM51.56%Profit Margin1.13%RSI (14)61.75Recom2.81
Dividend Gr. 3/5Y—Current Ratio4.66EPS Q/Q147.13%SMA208.42%Beta1.21Target Price30.89
Payout0.00%Debt/Eq0.08Sales Q/Q113.64%SMA509.47%Rel Volume0.61Prev Close25.24
Employees921LT Debt/Eq0.08EarningsNov 04SMA2003.97%Avg Volume881.15KPrice24.54
IPO DateFeb 24, 1992Option/ShortYes / YesEPS/Sales Surpr.-27.72% 3.24%Net Debt/EBITDA-4.72Volume535,472Change-2.77%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-29-26ReiteratedVeritas Investment Research$31
Sep-29-26UpgradeStifelHold → Buy
Sep-22-26ReiteratedJefferiesBuy$28 → $23
Aug-17-26ReiteratedUBSSell$19 → $28
Aug-13-26ReiteratedWilliam BlairMarket Perform$45 → $33
Aug-13-26ReiteratedUBSSell$19
Aug-13-26ReiteratedJefferiesBuy$60 → $28
May-14-26ReiteratedStifel Nicolaus$18 → $31
May-14-26UpgradeWedbushNeutral → Outperform$26 → $40
May-14-26ReiteratedCanaccord GenuityBuy$27 → $32
Latest News· Times ET
Oct-29-26
Oct-28-26
Oct-27-26
Oct-21-26
Oct-17-26
Oct-16-26
Oct-12-26
Oct-08-26
Oct-01-26
Sep-29-26
Sep-25-26
Company

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
1/2/2026
FY 2024
12/27/2024
FY 2023
12/29/2023
FY 2022
12/30/2022
FY 2021
12/31/2021
FY 2020
1/1/2021
FY 2019
1/3/2020
FY 2018
12/28/2018
Total Revenue341239314322—————
Cost of Goods Sold Incl. D&A81577470—————
Gross Profit260182240253—————
Selling, General and Administrative Excl. Other179188198180—————
Research and Development38405444—————
Other Operating Expense7001—————
Operating Income34-46-1328—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)-18-3646—————
Net Income Before Taxes17-82-934—————
Income Taxes14-21112—————
Consolidated Net Income4-80-2021—————
Net Income From Continuing Operations4-80-2021—————
Net Income4-80-2021—————
EPS (Recurring)0.08-1.62-0.410.44—————
EPS (Basic, Before Extraordinaries)0.08-1.62-0.410.44—————
EPS (Diluted)0.08-1.62-0.410.43—————
EBITDA32-74-239—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio306.75——72.58—————
Price To Sales Ratio3.604.943.784.75—————
Gross Margin76.2576.1576.4378.57—————
Operating Margin9.97-19.25-4.148.70—————
Net Margin1.17-33.47-6.376.52—————
Shares Outstanding50504949—————
Market Capitalization1,2271,1801,1861,529—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$35.93$30.32$24.72$19.12$13.51● Close Price0.00M10.27M20.53M30.80M41.06MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Foust WarrenPresident and CEOAug 14 '26Option Exercise0.0021,994097,553Aug 18
ANDREWS DEBORAH JChief Financial Officer & EVPAug 14 '26Option Exercise0.0010,466041,452Aug 18
Michna MagdaChief Development OfficerAug 14 '26Option Exercise2.1813,19828,79843,599Aug 18
ANDREWS DEBORAH JChief Financial Officer & EVPJul 31 '26Option Exercise0.0020,787046,915Aug 04
Foust WarrenPresident and CEOJul 31 '26Option Exercise0.0020,787097,132Aug 04
ANDREWS DEBORAH JChief Financial Officer & EVPJun 25 '26Option Exercise0.0013,955032,608Aug 04
Butcher Arthur CDirectorJun 18 '26Option Exercise0.005,34109,549Jun 22
SILVERMAN LOUDirectorJun 18 '26Option Exercise0.0010,683011,158Jun 22
Jiang WeiDirectorJun 18 '26Option Exercise0.0010,683077,127Jun 22
ANDREWS DEBORAH JInterim Co-CEO and CFOMay 15 '26Option Exercise0.0015,699015,699May 19
Foust WarrenInterim Co-CEO and Pres. & COOMay 15 '26Option Exercise0.0032,990032,990May 19
Michna MagdaChief Development OfficerMay 15 '26Option Exercise0.0019,795019,795May 19
Michna MagdaChief Development OfficerMar 14 '26Option Exercise0.0017,595036,001Mar 16
Foust WarrenInterim Co-CEO and Pres. & COOMar 14 '26Option Exercise0.0029,325063,588Mar 16
Foust WarrenInterim Co-CEO and Pres. & COOMar 12 '26Option Exercise0.008,175034,263Mar 16
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.